Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 13/20 | 0.61 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | CTSK | P43235 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21345164 | 0.99 | FOLH1 (0.60) | FOLH1MEN1KMT2AMAPTNPSR1 | |
| SCHEMBL12925116 | 0.96 | FOLH1 (0.57) | FOLH1MEN1KMT2AMAPTNPSR1 | |
| SCHEMBL20089634 | 0.93 | FOLH1 (0.72) | FOLH1CTSKATM | |
| SCHEMBL17937433 | 0.90 | FOLH1 (0.61) | FOLH1MEN1KMT2AMAPTNPSR1 | |
| SCHEMBL30022115 | 0.90 | FOLH1 (0.61) | FOLH1MEN1KMT2AMAPTNPSR1 | |
| SCHEMBL12925107 | 0.90 | FOLH1 (0.48) | FOLH1MEN1KMT2AMAPTNPSR1 | |
| SCHEMBL19874793 | 0.90 | FOLH1 (0.61) | FOLH1MEN1KMT2AMAPTNPSR1 | |
| SCHEMBL1077625 | 0.88 | FOLH1 (0.47) | FOLH1MEN1KMT2AMAPTNPSR1 | |
| SCHEMBL1077623 | 0.88 | FOLH1 (0.47) | FOLH1MEN1KMT2AMAPTNPSR1 | |
| SCHEMBL15449633 | 0.87 | FOLH1 (0.46) | FOLH1MEN1KMT2AMAPTNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210246103-A1 | HETERODIMERS OF GLUTAMIC ACID | CITIZENS BANK, N.A. | 2021-08-12 | — | — | US | disclosed |
| US-20210070695-A1 | HETERODIMERS OF GLUTAMIC ACID | MOLECULAR INSIGHT PHARMACEUTICALS, INC. | 2021-03-11 | — | — | US | disclosed |
| US-20210070696-A1 | HETERODIMERS OF GLUTAMIC ACID | MOLECULAR INSIGHT PHARMACEUTICALS, INC. | 2021-03-11 | — | — | US | disclosed |
| US-10647666-B2 | Heterodimers of glutamic acid | MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) | 2020-05-12 | — | — | US | disclosed |
| US-10640461-B2 | Heterodimers of glutamic acid | MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) | 2020-05-05 | — | — | US | disclosed |
| US-20190276393-A1 | Heterodimers of Glutamic Acid | MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) | 2019-09-12 | — | — | US | disclosed |
| US-20180111895-A1 | Heterodimers of Glutamic Acid | MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) | 2018-04-26 | — | — | US | disclosed |
| US-20180111895-A1 | Heterodimers of Glutamic Acid | MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) | 2018-04-26 | — | — | US | disclosed |
| US-9878980-B2 | Heterodimers of glutamic acid | MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) | 2018-01-30 | — | — | US | disclosed |
| US-9878980-B2 | Heterodimers of glutamic acid | MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) | 2018-01-30 | — | — | US | disclosed |
| US-9309193-B2 | Heterodimers of glutamic acid | MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) | 2016-04-12 | — | — | US | disclosed |
| US-9309193-B2 | Heterodimers of glutamic acid | MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) | 2016-04-12 | — | — | US | disclosed |
| US-8487129-B2 | Heterodimers of glutamic acid | MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) | 2013-07-16 | — | — | US | disclosed |
| US-8487129-B2 | Heterodimers of glutamic acid | MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) | 2013-07-16 | — | — | US | disclosed |
| US-20120269726-A1 | Heterodimers of Glutamic Acid | MOLECULAR INSIGHT PHARMACEUTICALS, INC. | 2012-10-25 | — | — | US | disclosed |
| US-20120269726-A1 | Heterodimers of Glutamic Acid | MOLECULAR INSIGHT PHARMACEUTICALS, INC. | 2012-10-25 | — | — | US | disclosed |
| US-20120208988-A1 | HETERODIMERS OF GLUTAMIC ACID | MOLECULAR INSIGHTS PHARMACEUTICALS, INC. (US) | 2012-08-16 | — | — | US | disclosed |
| US-20120208988-A1 | HETERODIMERS OF GLUTAMIC ACID | MOLECULAR INSIGHTS PHARMACEUTICALS, INC. (US) | 2012-08-16 | — | — | US | disclosed |
| US-20080193381-A1 | HETERODIMERS OF GLUTAMIC ACID | MOLECULAR INSIGHT PHARMACEUTICALS, INC. | 2008-08-14 | — | — | US | disclosed |
| US-20080193381-A1 | HETERODIMERS OF GLUTAMIC ACID | MOLECULAR INSIGHT PHARMACEUTICALS, INC. | 2008-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210070695-A1 | HETERODIMERS OF GLUTAMIC ACID | DDO, GLUL, ASNS | FOLH1 5/4885MEN1 2461/4885KMT2A 2413/4885 |
| US-20190276393-A1 | Heterodimers of Glutamic Acid | GLUL, DDO, ASNS | FOLH1 4/4885MEN1 2804/4885KMT2A 2234/4885 |
| US-10647666-B2 | Heterodimers of glutamic acid | DDO, GLUL, ASNS | FOLH1 5/4885MEN1 2461/4885KMT2A 2413/4885 |
| US-20120269726-A1 | Heterodimers of Glutamic Acid | DDO, GLUL, ASNS | FOLH1 5/4885MEN1 2384/4885KMT2A 2428/4885 |
| US-20080193381-A1 | HETERODIMERS OF GLUTAMIC ACID | DDO, GLUL, ASNS | FOLH1 5/4885MEN1 2461/4885KMT2A 2413/4885 |
| US-20210070696-A1 | HETERODIMERS OF GLUTAMIC ACID | DDO, GLUL, ASNS | FOLH1 5/4885MEN1 2472/4885KMT2A 2402/4885 |
| US-20120208988-A1 | HETERODIMERS OF GLUTAMIC ACID | DDO, GLUL, ASNS | FOLH1 5/4885MEN1 2461/4885KMT2A 2413/4885 |
| US-10640461-B2 | Heterodimers of glutamic acid | DDO, GLUL, ASNS | FOLH1 5/4885MEN1 2461/4885KMT2A 2413/4885 |
| US-20210246103-A1 | HETERODIMERS OF GLUTAMIC ACID | DDO, GLUL, ASNS | FOLH1 5/4885MEN1 2461/4885KMT2A 2413/4885 |
| US-20180111895-A1 | Heterodimers of Glutamic Acid | DDO, GLUL, ASNS | FOLH1 5/4885MEN1 2439/4885KMT2A 2466/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.